Based on results from the ongoing pharmacokinetic study (NCT06153758), Pfizer Inc. has selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist. Pfizer plans to conduct dose optimization studies in the second half of 2024 evaluating multiple doses of the preferred modified release formulation to inform the registration enabling studies. “Obesity is a key therapeutic area for Pfizer, and the company has a robu...